A Study to Learn About the Effects of the Combination of Elranatamab, Daratumumab and Lenalidomide Compared With Daratumumab, Bortezomib, Lenalidomide, and Dexamethasone in Patients With Newly Diagnosed Multiple Myeloma Who Are Not Candidates for Transplant

NCT05623020 · clinicaltrials.gov ↗

PHASE3

Phase

RECRUITING

Status

1116

Enrollment

INDUSTRY

Sponsor class

Conditions

Multiple Myeloma

Interventions

DRUG: Elranatamab
DRUG: Daratumumab
DRUG: Lenalidomide
DRUG: Dexamethasone
DRUG: Bortezomib

Sponsor

Pfizer